Volume 29, No 8, Aug 2019
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 29 Issue 8, August 2019: 601-602
RESEARCH HIGHLIGHTS
pH-sensitive anti-CTLA4 antibodies: yes to efficacy, no to toxicity
Amnon Altman 1 and Kok-Fai Kong 1
1Division of Cell Biology, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
Correspondence: Amnon Altman (amnon@lji.org)
For a long time, anti-CTLA-4 antibodies were believed to mediate their beneficial cancer immunotherapeutic effect (CITE), whose effectiveness and safety are limited by associated immune-related adverse effects (irAE), via blocking the interaction between CTLA-4 and its ligands, a mechanism known as checkpoint blockade. Using novel engineered antibodies, Zhang et al. challenge this paradigm in the present study, demonstrating that the irAE of anti-CTLA-4 antibodies can be uncoupled from their CITE, raising hopes for the design of a new generation of safer and more effective anti-CTLA-4 antibodies.
FULL TEXT | PDF
Browse 1026
